Curcumin

Curcumin is the yellow pigment in turmeric. In water it is nearly insoluble. That single property explains why an entire cottage industry of curcumin formulations, nanoparticle, liposomal, piperine-combined, phospholipid-complexed, exists: plain curcumin barely gets into the bloodstream in usable amounts.

The most cited fix is piperine, the active compound in black pepper. Shoba and colleagues in 1998 gave human volunteers 2g of curcumin alone versus 2g of curcumin plus 20mg piperine, and found piperine increased curcumin bioavailability by 2000% [1]. That number gets repeated constantly in marketing copy. It is real, but it measures blood concentration of curcumin and its metabolites, not a clinical outcome.

When curcumin is tested against actual outcomes, results are mixed and modest. A 2016 randomized, double-blind, placebo-controlled trial in community-dwelling older adults found no significant effect of curcumin on the primary cognitive outcome measures, despite some secondary improvements in mood [2]. A 2019 meta-analysis of RCTs on inflammatory markers in chronic inflammatory disease found curcumin reduced CRP and other inflammatory markers across pooled trials, a positive but modest signal, and the authors flagged substantial heterogeneity in formulations and doses used across the included studies [3].

What the evidence does not show: that any commercially available curcumin formulation reliably reaches the same plasma concentrations used in cell-culture experiments showing anti-cancer or anti-inflammatory effects. A 2025 pharmacokinetic reappraisal found that even with piperine or other enhanced-uptake formulations, plasma levels of unconjugated, biologically active curcumin remain minimal in humans, well below concentrations shown to have direct effects in vitro [4]. That is the central unresolved gap in curcumin research: cell-culture and animal doses do not translate into achievable human blood levels.

Blueprint's connection to curcumin is indirect. Bryan Johnson's Peak Performance Stack lists an "NAC Ginger Curcumin" capsule, taken three times daily, as part of his documented protocol [5]. The official page does not specify the curcumin dose or formulation, and Johnson has not published data isolating curcumin's individual contribution to any of his tracked biomarkers.

Critics of curcumin research point to two separate problems. First, curcumin is a PAINS compound, pan-assay interference substance, in medicinal chemistry terms: it reacts nonspecifically with many protein assay targets in vitro, which inflates the number of "mechanisms" attributed to it in the literature without necessarily reflecting real pharmacology in a living human. Second, the bioavailability problem above means most positive cell-culture findings may simply not be reachable at safe oral doses.

The honest takeaway: curcumin has real anti-inflammatory signal in human trials at pooled analysis, but the effect is modest, formulation-dependent, and nowhere near what cell-culture studies would predict from the concentrations used in a dish.

Products with this: Curcumin